BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22551846)

  • 21. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes.
    Uber WE; Toole JM; Stroud MR; Haney JS; Lazarchick J; Crawford FA; Ikonomidis JS
    J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1469-77.e2. PubMed ID: 21457998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.
    Gill R; Herbertson M; Vuylsteke A; Olsen PS; von Heymann C; Mythen M; Sellke F; Booth F; Schmidt TA
    Circulation; 2009 Jul; 120(1):21-7. PubMed ID: 19546387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose recombinant factor VIIa for reversing coagulopathy in patients with isolated traumatic brain injury.
    Yuan Q; Wu X; Du ZY; Sun YR; Yu J; Li ZQ; Wu XH; Mao Y; Zhou LF; Hu J
    J Crit Care; 2015 Feb; 30(1):116-20. PubMed ID: 25092615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
    Chapman AJ; Blount AL; Davis AT; Hooker RL
    Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant factor VIIa use in acute type A aortic dissection repair: A multicenter propensity-score-matched report from the Nordic Consortium for Acute Type A Aortic Dissection.
    Zindovic I; Sjögren J; Ahlsson A; Bjursten H; Fuglsang S; Geirsson A; Ingemansson R; Hansson EC; Mennander A; Olsson C; Pan E; Ullén S; Gudbjartsson T; Nozohoor S
    J Thorac Cardiovasc Surg; 2017 Dec; 154(6):1852-1859.e2. PubMed ID: 28967418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithrombotic and hemostatic stewardship: evaluation of clinical outcomes and adverse events of recombinant factor VIIa (Novoseven
    Marsh K; Green D; Raco V; Papadopoulos J; Ahuja T
    Ther Adv Cardiovasc Dis; 2020; 14():1753944720924255. PubMed ID: 32449469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant activated factor VII for hemostasis in patients undergoing complex ascending aortic surgery: A single-center, single-surgeon retrospective analysis.
    Hang D; Koss K; Rokkas CK; Pagel PS
    J Card Surg; 2021 Dec; 36(12):4558-4563. PubMed ID: 34608671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
    Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
    Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bivalirudin for anticoagulation during hypothermic cardiopulmonary bypass and recombinant factor VIIa for iatrogenic coagulopathy.
    Nagle EL; Tsu LV; Dager WE
    Ann Pharmacother; 2011 Sep; 45(9):e47. PubMed ID: 21862711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII.
    Bruckner BA; DiBardino DJ; Ning Q; Adeboygeun A; Mahmoud K; Valdes J; Eze J; Allison PM; Cooley DA; Gregoric ID; Frazier OH
    J Heart Lung Transplant; 2009 Aug; 28(8):785-90. PubMed ID: 19632574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Recombinant Factor VII as Rescue for Severe Perioperative Bleeding in HeartMate II Recipients.
    Karimi A; Daigle SS; Smith WB; Janelle GM; Klodell CT
    J Card Surg; 2015 Jun; 30(6):500-5. PubMed ID: 25939953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant-activated factor VII in the paediatric cardiac surgery: single unit experience.
    Agarwal V; Okonta KE; Lal PS
    Afr J Paediatr Surg; 2012; 9(3):193-7. PubMed ID: 23250238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
    Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
    Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
    Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The use of recombinant activated factor VII for blood loss after cardiovascular surgery].
    Gong ZY; Gao CQ; Xiao CS; Li BJ; Ma XH; Zhang CM
    Zhonghua Wai Ke Za Zhi; 2008 Oct; 46(19):1497-501. PubMed ID: 19094631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Very low-dose recombinant Factor VIIa administration for cardiac surgical bleeding reduces red blood cell transfusions and renal risk: a matched cohort study.
    Cotter E; Sharma A; Campton A; Gao G; He J; Wirtz K; Zorn T; Flynn BC
    Blood Coagul Fibrinolysis; 2021 Oct; 32(7):473-479. PubMed ID: 34650021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of recombinant activated factor VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: a single center review.
    Long MT; Wagner D; Maslach-Hubbard A; Pasko DA; Baldridge P; Annich GM
    Perfusion; 2014 Mar; 29(2):163-70. PubMed ID: 23942787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery.
    Bishop CV; Renwick WE; Hogan C; Haeusler M; Tuckfield A; Tatoulis J
    Ann Thorac Surg; 2006 Mar; 81(3):875-9. PubMed ID: 16488687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy.
    Ekert H; Brizard C; Eyers R; Cochrane A; Henning R
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):389-95. PubMed ID: 16788315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
    Pychyńska-Pokorska M; Pągowska-Klimek I; Krajewski W; Moll JJ
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):987-94. PubMed ID: 21835642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.